Dianthus Therapeutics, Inc. (DNTH) SEC filings

DNTHNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30

$92.48+3.18 (+3.56%)

Close on Nov 12, 2026Market cap $5.17BP/E –Yield 0.00%

SEC filings

40 of Dianthus Therapeutics's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 4, 2026	SEC EDGAR
Current report	8-K	Nov 4, 2026	Nov 4, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 4, 2026	SEC EDGAR
Current report	8-K	Aug 4, 2026	Aug 4, 2026	SEC EDGAR
Current report	8-K	Jun 12, 2026	Jun 12, 2026	SEC EDGAR
Current report	8-K	May 21, 2026	May 22, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 5, 2026	SEC EDGAR
Current report	8-K	May 5, 2026	May 5, 2026	SEC EDGAR
Proxy statement	DEF 14A	May 21, 2026	Apr 9, 2026	SEC EDGAR
Current report	8-K	Mar 26, 2026	Mar 26, 2026	SEC EDGAR
Current report	8-K	Mar 10, 2026	Mar 12, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 9, 2026	SEC EDGAR
Current report	8-K	Mar 9, 2026	Mar 9, 2026	SEC EDGAR
Current report	8-K	Jan 12, 2026	Jan 12, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 5, 2025	SEC EDGAR
Current report	8-K	Nov 5, 2025	Nov 5, 2025	SEC EDGAR
Current report	8-K	Nov 3, 2025	Nov 3, 2025	SEC EDGAR
Current report	8-K	Oct 16, 2025	Oct 16, 2025	SEC EDGAR
Current report	8-K	Sep 9, 2025	Sep 11, 2025	SEC EDGAR
Current report	8-K	Sep 8, 2025	Sep 8, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 7, 2025	SEC EDGAR
Current report	8-K	Aug 7, 2025	Aug 7, 2025	SEC EDGAR
Current report	8-K	May 22, 2025	May 22, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 12, 2025	SEC EDGAR
Current report	8-K	May 12, 2025	May 12, 2025	SEC EDGAR
Proxy statement	DEF 14A	May 22, 2025	Apr 10, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 11, 2025	SEC EDGAR
Current report	8-K	Mar 11, 2025	Mar 11, 2025	SEC EDGAR
Current report	8-K	Mar 4, 2025	Mar 5, 2025	SEC EDGAR
Current report	8-K	Dec 12, 2024	Dec 12, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 7, 2024	SEC EDGAR
Current report	8-K	Nov 7, 2024	Nov 7, 2024	SEC EDGAR
Current report	8-K	Sep 16, 2024	Sep 16, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 8, 2024	SEC EDGAR
Current report	8-K	Aug 8, 2024	Aug 8, 2024	SEC EDGAR
Current report	8-K	Jun 6, 2024	Jun 6, 2024	SEC EDGAR
Current report	8-K	May 23, 2024	May 28, 2024	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2024	May 9, 2024	SEC EDGAR
Current report	8-K	May 9, 2024	May 9, 2024	SEC EDGAR
Proxy statement	DEF 14A	May 23, 2024	Apr 11, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Dianthus Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-67 reverse split on Nov 9, 2023
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is DNTH.

Compare: DNTH vs UPB · DNTH vs CNTB · DNTH vs RNAC · DNTH vs ACRS · DNTH vs YARW

Revenue growth-67.3% · median 0.2%

Operating margin-11592.7% · median -6116.0%

Net margin-9927.5% · median -5712.3%

Company	Revenue	Growth
ACRS	$6.40M	-59.3%
CNTB	$2.95M	+50.3%
UPB	$2.87M	+2.5%
DNTH	$2.04M	-67.3%
RNAC	$1.03M	–
YARW	$476.00K	-2.1%

Company

Next earnings (est.): Mar 8, 2027, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 92
Held by institutions: 100.0%
Auditor: Deloitte & Touche LLP
SEC CIK: 1690585

Advertisement
300 × 250

See a number that looks wrong?